Docsity
Docsity

Prepare for your exams
Prepare for your exams

Study with the several resources on Docsity


Earn points to download
Earn points to download

Earn points by helping other students or get them with a premium plan


Guidelines and tips
Guidelines and tips

Enucleated Cell - Biotechnology - Exam, Exams of Biotechnology

Enucleated Cell, Better to Target, Cancer Stem Cells, Normal Cancer Cells, Nanoparticle, Bioremediation, Bioterrorist Attack, Model Organism, Brain Function, Proteasome are some important points from questions.

Typology: Exams

2011/2012

Uploaded on 11/30/2012

gurudev
gurudev 🇮🇳

4.6

(10)

102 documents

1 / 5

Toggle sidebar

This page cannot be seen from the preview

Don't miss anything!

bg1
SUMMER EXAMINATIONS 2011
Denominated Degree in Biotechnology (2BY1)
BIOTECHNOLOGY II (BG 202)
External Examiner: Dr. Michael Stark
Internal Examiners: Dr Adrienne Gorman, Dr Muriel Grenon, Dr Eva Szegezdi, Dr
Maria Tuohy, Prof Bob Lahue, Dr Peter Creighton, Prof Kevin
Sullivan
Discipline: Biochemistry
Number of pages: 5
Time Allowed: Three hours
Instructions
Your answers to Section A should be written directly onto the examination paper
which must be handed up at the end of the examination. This is worth 40% of the
marks.
Your answers to Section B should be written into answer books. This is worth 60% of
the marks.
Section A
Student number: ______________________________________
Name: _______________________________________________
pf3
pf4
pf5

Partial preview of the text

Download Enucleated Cell - Biotechnology - Exam and more Exams Biotechnology in PDF only on Docsity!

SUMMER EXAMINATIONS 2011

Denominated Degree in Biotechnology (2BY1)

BIOTECHNOLOGY II (BG 202)

External Examiner: Dr. Michael Stark Internal Examiners: Dr Adrienne Gorman, Dr Muriel Grenon, Dr Eva Szegezdi, DrMaria Tuohy, Prof Bob Lahue, Dr Peter Creighton, Prof Kevin

Discipline: SullivanBiochemistry Number of pages: 5 Time Allowed: Three hours

Instructions Your answers to Section A should be written directly onto the examination paper

which must be handed up at the end of the examination. This is worth 40% of themarks.

Your answers tothe marks. Section B should be written into answer books. This is worth 60% of

Section A

Student number: ______________________________________

Name: _______________________________________________

Section A. Answer ALL questions in this section, and hand up

with your answer book.

  1. What is an enucleated cell?





  2. Why is it better to target cancer stem cells rather than normal cancer cellsin a tumour?






  1. Give the name of a nanoparticle that can be used for targeted drugdelivery and briefly describe how it works.






  1. What is the name of the “Tag” that causes a protein to be targeted to theproteasome? What happens to the tagged protein once it reaches the proteasome?





  1. Describe what can NUDE mice be used for and why.





  2. Inbrains? Alzheimer’s disease, what protein is found in plaques in affected


  1. Describeantibiotics. two tactics that superbugs use to become resistant to





SUMMER EXAMINATIONS 2011

Denominated Degree in Biotechnology (2BY1)

BIOTECHNOLOGY II (BG 202)

External Examiner: Dr. Michael Stark

Section B. Answer any TWO of the following questions

  1. What are the two main protein-degrading mechanisms in eukaryoticcells? Describe the functions of the two systems and give an example how their deficiency can contribute to diseases.
  2. Writeunderstanding and treating an essay on the (^) either developments viral infections such as those caused that have been made in by influenzadisease. or HIV, or gastrointestinal disorders such as Coeliac
  3. Answer bothA) Define ‘optogenetics’ and outline how it works (8 points). parts of this question on Optogenetics. B) Briefly explain how only one type of neuron in a mouse braincan be programmed to make the opsin protein (2 points).
  4. ‘Animal models have provided new insights into our understanding ofmemory’. Discuss this statement using two specific examples of animal models.
  5. Discuss the relative strengths and weaknesses of chemotherapeuticversus vaccine-based strategies for controlling pathogen-mediated diseases, including the role(s) played by genomic technologies.